Cancer neoantigens as potential targets for immunotherapy
| العنوان: | Cancer neoantigens as potential targets for immunotherapy |
|---|---|
| المؤلفون: | Tianhong Li, Weijie Ma, Brian Pham |
| المصدر: | Clinical & experimental metastasis, vol 39, iss 1 Clinical & Experimental Metastasis |
| بيانات النشر: | eScholarship, University of California, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_treatment, Disease, Review, Medical Oncology, Surgical oncology, Neoplasms, Cancer vaccine, Medicine, Cancer, screening and diagnosis, Tumor, General Medicine, Detection, 5.1 Pharmaceuticals, Tumor genomic profiling, Biomarker (medicine), Microsatellite Instability, Immunotherapy, Development of treatments and therapeutic interventions, Biotechnology, medicine.medical_specialty, Clinical Sciences, Oncology and Carcinogenesis, Vaccine Related, Rare Diseases, Internal medicine, Biomarkers, Tumor, Genetics, Humans, Oncology & Carcinogenesis, Personalized immunotherapy, business.industry, (4–6) Cancer neoantigen, Human Genome, Microsatellite instability, medicine.disease, Tumor mutational burden, 4.1 Discovery and preclinical testing of markers and technologies, Good Health and Well Being, Cancer cell, Mutation, Immunization, business, Biomarkers |
| الوصف: | Immune checkpoint inhibitors (ICIs) targeting the cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and programed cell death protein 1 (PD-1) or its ligand PD-L1 have increased the survival and cure rates for patients with many cancer types in various disease settings. However, only 10–40% of cancer patients benefited from these ICIs, of whom ~ 20% have treatment interruption or discontinuation due to immune-related adverse events that can be severe and even fatal. Current efforts in precision immunotherapy are focused on improving biomarker-based patient selection for currently available ICIs and exploring rationale combination and novel strategies to expand the benefit of immunotherapy to more cancer patients. Neoantigens arise from ~ 10% of the non-synonymous somatic mutations in cancer cells, are important targets of T cell-mediated anti-tumor immunity for individual patients. Advances in next generation sequencing technology and computational bioinformatics have enable the identification of genomic alterations, putative neoantigens, and gene expression profiling in individual tumors for personal oncology in a rapid and cost-effective way. Among the genomic biomarkers, defective mismatch DNA repair (dMMR), microsatellite instability high (MSI-H) and high tumor mutational burden (H-TMB) have received FDA approvals for selecting patients for ICI treatment. All these biomarkers measure high neoantigen load and tumor antigenicity, supporting the current development of neoantigen-based personalized cancer vaccines for patients with high TMB tumor. Several studies have shown neoantigen vaccines are feasible, safe and have promising clinical activity in patients with high TMB tumors in both metastatic and adjuvant settings. This review summarizes the emerging data and technologies for neoantigen-based personalized immunotherapy. |
| وصف الملف: | application/pdf |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b8d0434ff1e8abf8af42687954328fe https://escholarship.org/uc/item/2w39365h |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....9b8d0434ff1e8abf8af42687954328fe |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |